Abstract Details

Title Epidemiological and Seasonal Characteristics of Vestibular Neuritis

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) P02 - (-)

Poster/Presentation
Number 249

Objective

Background BACKGROUND: VN is manifested as a prolonged vertigo crisis of sudden onset. It is the most common cause of acute unilateral vestibular hypofunction and the third leading cause of vertigo in general. The theory of a viral origin is widely accepted, although it has been postulated a possible vascular origin.

Design/Methods DESIGN/METHODS: We retrospectively analyzed medical records of patients who were admitted to the ER and met clinical criteria for acute peripheral vestibular hypofunction, presenting vertigo at least 24 hours before. For categorical and continuous data were used percentage and average with its SD respectively. Continuous data were compared using t test and chi2 for categorical data. p <0.05 was considered significant.

Results RESULTS: Of 2303 patients presenting with dizziness and vertigo; 89 patients met the criteria. 33 (37%) were female and the mean age at presentation was 48.2 years (+/- 18). 14 (15.5%) were presented during summer, 16 (17.17%) during autom, 48 (53,3%) during winter and 12 (13.3%) during spring. The average duration of the event was 6 days (± 5 days). 51 (56.7%) patients were younger than 50 years and 39 (43.3%) older. A previuos infection was observed in 30%. We performed a comparative analysis of subpopulations: under 50 years old (56.7%) vs older (43.3%) in which there was a statistically significant difference regarding: the presence of vascular risk factors (p <0.001); winter seasonal presence for the younger group (35vs13)(p <0.001) and in summer in favor of the older group (2vs12)(p <0.001).

Conclusions CONCLUSIONS: The finding of a seasonal component in this pathology, which significantly increases when is subdivided by age, associated with the presence of vascular risk factors in the older group suggest a different aetiology in these populations with similar clinical manifestations.

Authors/Disclosures
Guillermo Videla, MD (Hospital Italiano De Buenos Aires) PRESENTER	No disclosure on file
	No disclosure on file
Lucia Ciancaglini	No disclosure on file
Vanesa Pytel	No disclosure on file
Jorge O. Norscini, MD	No disclosure on file
	No disclosure on file
Edgardo Cristiano, MD (Hospital Italiano De Buenos Aires)	Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Allan G. Kermode, MD, MBBS, FRACP (SJOG Clinic, Suite 314)	Dr. Kermode has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kermode has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche.

��ɫ��

��ɫ��